Penumbra, Inc. announced that its RED®Reperfusion Catheters have secured CE Mark (Conformité Européenne) and are now commercially available in Europe. The catheters are part of the company's Penumbra System®, which is a fully integrated mechanical aspiration thrombectomy system designed to restore blood flow in acute ischemic stroke (AIS) patients. The RED family of catheters is engineered with the latest technology in trackability and aspiration to address a wide range of large vessel occlusions via mechanical aspiration thrombectomy.

The RED catheters feature REDglide™ technology, which enhances the trackability of the catheters as they navigate the challenging vessel anatomy of the brain while also maximizing aspiration efficiency to remove blood clots. Additionally, the RED catheters have a full-length PTFE liner designed to maintain their true lumen size under powerful vacuum. Initial INSIGHT Registry data presented in August at the World Federation of Interventional and Therapeutic Neuroradiology (WFITN) showed Penumbra's RED® reperfusion catheters were successful in removing all clot types with a significant first pass rate.

The data from 161 AIS patients showed 68.9% successful first-pass revascularization (mTICI=2b-3), and 97% successful revascularization after final angiogram through site reported findings. Final mTICI=2b-3 scores were reported in 98.1% of patients with firm-red clots and in 100% of patients with other clot types.